Conference LibraryGated
Claim · in vivo CAR-T safety profile distinct from ex vivo CRS · vector-infusion-related toxicity
ESO-T01 phase 1 reports CRS in 4/5 patients (3 grade 3) + 1 grade 1 ICANS · toxicity timing post-vector-infusion (NOT post-CAR-T-cell- infusion as in ex vivo) · vector-infusion-related toxicity is a safety axis unique to in vivo CAR-T · NOT directly comparable to ex vivo CRS pro…
- Type
- claim
- Domain
- car-t
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- safety_distinction_claim
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "early IIT phase 1 safety signal · NOT validated late-stage model · not intended to guide individual patient treatment choices"
- claim_statement
- ESO-T01 phase 1 reports CRS in 4/5 patients (3 grade 3) + 1 grade 1 ICANS · toxicity timing post-vector-infusion (NOT post-CAR-T-cell- infusion as in ex vivo) · vector-infusion-related toxicity is a safety axis unique to in vivo CAR-T · NOT directly comparable to ex vivo CRS prof
- claim_evidence_grade
- A
- supporting_papers
- m622-b5-paper-naturemed-esot01-001,m622-b5-paper-inside-precision-medicine-2026-001
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.